[Federal Register Volume 84, Number 100 (Thursday, May 23, 2019)]
[Notices]
[Pages 23759-23760]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10805]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-36-2019]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Notification 
of Proposed Production Activity, Bristol-Myers Squibb Holdings Pharma, 
Ltd. (Pharmaceuticals), Manati, Puerto Rico

    Bristol-Myers Squibb Holdings Pharma, Ltd. (BMS) submitted a 
notification of proposed production activity to the FTZ Board for its 
facility in Manati, Puerto Rico. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on May 13, 2019.
    BMS already has authority to produce certain pharmaceutical 
products within Subzone 7J. The current request would add finished 
products and a foreign status material/component to the scope of 
authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would 
be limited to the specific foreign-status material/component and 
specific finished products described in the submitted notification (as 
described below) and subsequently authorized by the FTZ Board.

[[Page 23760]]

    Production under FTZ procedures could exempt BMS from customs duty 
payments on the foreign-status materials/components used in export 
production. On its domestic sales, for the foreign-status material/
component noted below and in the existing scope of authority, BMS would 
be able to choose the duty rates during customs entry procedures that 
apply to pegbelfermin in measured and finished dosages (duty-free). BMS 
would be able to avoid duty on foreign-status components which become 
scrap/waste. Customs duties also could possibly be deferred or reduced 
on foreign-status production equipment.
    The material/component sourced from abroad is pegbelfermin--active 
pharmaceutical ingredient (duty-free).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is July 2, 2019.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected] or (202) 482-1963.

    Dated: May 17, 2019.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2019-10805 Filed 5-22-19; 8:45 am]
BILLING CODE 3510-DS-P